Up to $2.2 Billion Zantac Settlement Resolves Roughly 80,000 Cancer Lawsuits

New to ClassAction.org? Read our Newswire Disclaimer

GSK has agreed to pay up to $2.2 billion to settle approximately 80,000 Zantac lawsuits filed nationwide that alleged the heartburn medication can cause cancer.

Don’t miss out on settlement news like this. Sign up for ClassAction.org’s free weekly newsletter.

In a statement posted on its website, GSK relayed that the up to $2.2 billion settlement ends 93 percent of all Zantac cancer lawsuits filed in U.S. state courts. Class action attorneys from 10 law firms participating in the settlement have unanimously recommended that clients accept the terms of the Zantac settlement, which GSK agreed to fully implement by the end of the first half of 2025, the company said.

Per GSK’s statement, the terms of the Zantac settlement agreements are confidential. GSK also confirmed in the announcement that it had reached an agreement in principal to pay $70 million to resolve a qui tam whistleblower complaint filed by independent laboratory Valisure.

In May 2024, drug maker and Zantac seller Sanofi agreed to pay $100 million to settle 4,000 personal injury claims filed by individuals who alleged the company failed to warn them that Zantac can cause cancer.

GSK has not admitted to any liability in the state courts settlement or agreement in principle qui tam settlement. The company stated that while the “scientific consensus remains that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer, GSK strongly believes that these settlements are in the best long-term interests of the company and its shareholders as they remove significant financial uncertainty, risk and distraction associated with protracted litigation.”

Zantac, which was first approved by federal regulators in 1983, became the world’s best-selling medicine in 1988 and one of the first to surpass $1 billion in annual sales. Zantac has been sold at various times by GSK, Pfizer, Sanofi and Boehringer Ingelheim, which is currently in an ongoing trial over Zantac in California.

The majority of the remaining Zantac lawsuits are in Delaware state court, where a judge in June allowed plaintiffs to present expert testimony that Zantac caused cancer, Reuters reports.

Zantac is currently sold under the name Zantac 360, with a different active ingredient and no ranitidine.

Are you owed unclaimed settlement money? Check out our class action rebates page full of open class action settlements.